Oran Diagnostics Announces Appointments to Scientific Advisory Board

BERWYN, PA, October 12, 2010—Oran Diagnostics, LLC, a specialized medical device company developing novel clinical diagnostic tools for applications across a broad spectrum of disease states, today announced that it has finalized the composition of its scientific advisory board with the addition of two new members. Comprised of world-renowned cardiologists and scientists, the advisory board will play an important role in guiding and participating in Oran’s research and clinical development programs.

“Oran is very fortunate to have such distinguished physicians and scientists as advisors to guide Oran in the development of the TCL Analyzer ™ and its lead product candidate, TCL-HF ™,” said Bruce J. Goldstein, President and Chief Executive Officer of Oran . “Each member of our Scientific Advisory Board is highly influential in their respective fields, and their collective experience will be of tremendous value in every facet of Oran’s development and clinical programs."

The two latest appointments to the Scientific Advisory Board are:

William T. Abraham, MD, FACP, FACC, FAHA, FESC, Director, Division of Cardiovascular Medicine, Professor of internal medicine, physiology and cell biology at The Ohio State University Medical Center. Deputy Director, Dorothy M. Davis Heart and Lung Research Institute; Chair of Excellence in Cardiovascular Medicine at Ohio State’s College of Medicine.

Dr. Abraham earned his medical degree from Harvard Medical School in Boston, Massachusetts, following which he completed his residency in Internal Medicine and fellowships in Cardiology and Heart Failure/Cardiac Transplantation at the University of Colorado Health Sciences Center. He previously held faculty appointments at the University of Colorado, the University of Cincinnati, and the University of Kentucky. He is board certified in Internal Medicine and in Cardiovascular Diseases. Dr. Abraham’s research interests include the role of the kidney in heart failure, neurohormonal mechanisms in heart failure, systemic and cardiac adrenergic activity in heart failure, and clinical drug and device trials in heart failure and cardiac transplantation. He has participated as Principal Investigator in more than 100 multicenter clinical drug and device trials. In addition to authoring more than 250 original papers, abstracts, book chapters, and review articles, Abraham serves on the editorial boards of several major journals including the Journal of Cardiac Failure, Congestive Heart Failure, and Journal Watch Cardiology. He is also a scientific reviewer for such publications as Circulation, the European Heart Journal, and the Journal of the American College of Cardiology.

Harry Ischiropoulos, Ph.D., Research Professor of Pediatrics and Pharmacology, Mahoney Institute of Neurological Science, Univ. of Pennsylvania.

Dr. Ischiropoulos received his PhD in Experimental Pathology from New York Medical College. After post-doctoral training at the University of Alabama in Birmingham he joined the Department of Biochemistry and Biophysics at the University of Pennsylvania as a Research Assistant Professor. In 1998 he moved to the Children’s Hospital of Philadelphia Research Institute where he is presently a Joseph Stokes Jr. Investigator and the Gisela and Dennis Alter Research Professor of Pediatrics and Pharmacology. He held a Parker B. Francis Fellowship in Pulmonary Research from 1993-1996 and was an Established Investigator of the American Heart Association from 1996 to 2001. Dr. Ischiropoulos serves on the Editorial Boards of Journal of Biological Chemistry and Free Radical Biology and Medicine where he is an Associate Editor. Laboratory investigations have been focused on the biological chemistry of nitric oxide and oxidative stress in the cardiovascular and central nervous systems. Dr. Ischiropoulos also served as a co-chair of the 2004 Gordon conference on Oxygen Radicals and is presently the president of the Society for Free Radical Biology and Medicine (2010-2012).

Drs. Abraham and Ischiropoulos join the following members of Oran’s Scientific Advisory Board:

* Frank Smart, MD, Chairman, Department of Cardiovascular Medicine, Atlantic Health (Morristown, NJ); Chief of Cardiology at the Gagnon Heart Hospital, Morristown Memorial Hospital.
* Offer Amir, MD, Director, Heart Failure, Department of Cardiovascular Medicine, Lady Davis Carmel Medical Center, Haifa, Israel.
* Aaron Ciechanover, MD, D.Sc., Distinguished University Professor, Faculty of Medicine, Technion-Israel Institute of Technology; Laureate, the 2004 Nobel Prize in Chemistry.
* Michael M. Givertz, MD, Medical Director, Heart Transplant and Circulatory Assist Program, Brigham and Women's Hospital, Boston, MA; Associate Professor, Harvard Medical School.
* Hyman Schipper, MD, PhD, FRCPC, Professor of Neurology & Medicine, at McGill University; Director, Centre for Neurotranslational Research, Lady Davis Institute, Jewish General Hospital (JGH), Montreal, Quebec.

About Oran Diagnostics

Oran Diagnostics, LLC is using its proprietary device (the TCL Analyzer ™) and method (thermochemiluminescence) to develop accurate, minimally invasive clinical tools for use in clinical diagnostics, and for drug discovery and development. The company’s proprietary technology is currently being applied in cardiovascular and neurodegenerative disease. Oran Diagnostics is headquartered in Berwyn, PA, with research and development facilities in Haifa, Israel. For more information, please visit www.orandx.com.

TCL-HF™ is a rapid, minimally invasive procedure for designed to aid in the risk stratification of patients diagnosed with heart failure. The TCL Analyzer™ measures lipid peroxidation in a small sample (50 microlitres) of blood serum. Using a highly sensitive, proprietary method of biomarker identification (thermochemiluminescence), TCL-HF™ measures the level of oxidative stress and oxidizability, which measurement correlates with the degree of disease severity. Analysis can be performed in a hospital or clinical laboratory in just minutes. TCL-HF™ provides a relevant, previously unavailable clinical data point that helps guide treatment options for patients with heart failure. The TCL Analyzer™ and TCL-HF™ are not currently cleared for use in the U.S. by the Food and Drug Administration.

Contact: Meredith Hegg
491 Baltimore Pike Suite 209
Springfield, PA 19064
Phone: 610-626-0175

This release was published on openPR.